107 related articles for article (PubMed ID: 29263155)
1. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
Shureiqi I
Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
[TBL] [Abstract][Full Text] [Related]
6. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
[TBL] [Abstract][Full Text] [Related]
7. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
9. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis.
Thiruvengadam SS; OʼMalley M; LaGuardia L; Lopez R; Wang Z; Shadrach BL; Chen Y; Li C; Veigl ML; Barnholtz-Sloan JS; Pai RK; Church JM; Kalady MF; Walsh RM; Burke CA
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00053. PubMed ID: 31211760
[TBL] [Abstract][Full Text] [Related]
11. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
[TBL] [Abstract][Full Text] [Related]
14. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention in familial adenomatous polyposis.
Kim B; Giardiello FM
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
[TBL] [Abstract][Full Text] [Related]
16. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
17. Gastroduodenal lesions in familial adenomatous polyposis.
Kashiwagi H; Spigelman AD
Surg Today; 2000; 30(8):675-82. PubMed ID: 10955728
[TBL] [Abstract][Full Text] [Related]
18. [Chemoprevention of familial cancer].
Ishikawa H
Gan To Kagaku Ryoho; 1997 Jun; 24(8):951-7. PubMed ID: 9212803
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM
Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]